Autolus Therapeutics to participate in upcoming virtual investor conferences

Rhea-AI Summary

Autolus Therapeutics plc (Nasdaq: AUTL) has announced its participation in three upcoming virtual investor conferences. These events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, the Wells Fargo Healthcare Conference on September 10 at 7:30 am ET, and the H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Audiences can access live audio webcasts of the presentations through the company's website, with archived versions available for a limited time.

Autolus is focused on developing innovative T cell therapies to treat various cancers.

- Goldman Sachs Eleventh Annual Biotech Symposium on September 7

- 2021 Virtual Wells Fargo Healthcare Conference on September 10 at 7.30am ET

- H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13, at 7.00am ET

LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in three upcoming virtual investor conferences. An audio webcast of any presentations will be available live. You can access the webcasts via the Events section of the Autolus website. An archived version will also be available through the Company’s website for a limited time following the conference.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Business Strategy and Planning
+44 (0) 7587 372 619 
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

 

FAQ

What events is Autolus Therapeutics participating in September 2021?

Autolus Therapeutics will participate in the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, the Wells Fargo Healthcare Conference on September 10 at 7:30 am ET, and the H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13 at 7:00 am ET.

How can I access the webcasts of Autolus Therapeutics' presentations?

You can access the live audio webcasts of Autolus Therapeutics' presentations through the Events section of their website. Archived versions will also be available for a limited time.

What is the focus of Autolus Therapeutics' research?

Autolus Therapeutics is developing next-generation programmed T cell therapies for the treatment of cancer, targeting hematological malignancies and solid tumors.

When is the Wells Fargo Healthcare Conference taking place?

The Wells Fargo Healthcare Conference will take place on September 10, 2021, at 7:30 am ET.

Where can I find more information about Autolus Therapeutics?

More information about Autolus Therapeutics can be found on their official website at www.autolus.com.